STAT+: Eli Lilly says Verve’s gene editor lowers cholesterol levels in early study
Jason Mast·
·1 min read
·
0 reactions
·
0 comments
·
27 views
Eli Lilly said Monday that a high dose of its gene-editing therapy reduced cholesterol levels by 62% in participants in a clinical trial.
Original article
STAT · Jason Mast
Anonymous · no account needed
Discussion
0 commentsMore from STAT
Opinion: How the Amish think about vaccines, health care costs, and much more
STAT·12
Opinion: I led the U.S. CDC response to the 2014 Ebola epidemic. The new outbreak needs massive, immediate, meticulous action
STAT·12
STAT+: Newer GLP-1s, pushback on research cuts, and a protest
STAT·15
STAT+: Up and down the ladder: The latest comings and goings
STAT·12
STAT+: Will Makary’s FDA voucher program survive?
STAT·15
STAT+: Drug companies, patient groups urge FDA to pause commissioner’s voucher program
STAT·24